4.7 Article

Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection

期刊

LIVER INTERNATIONAL
卷 42, 期 6, 页码 1287-1296

出版社

WILEY
DOI: 10.1111/liv.15173

关键词

antibody response; CHB; cirrhosis; COVID-19 vaccine; safety

资金

  1. National Natural Science Foundation of China [81772198]
  2. National Science and Technology Major Project [2017ZX10202203-007, 2017ZX10202203-008, 2018ZX10302206-003]
  3. Natural Science Foundation of Chongqing [cstc2020jcyj-msxmX0389]
  4. a pilot project of clinical cooperation between traditional Chinese and western medicine for significant and complicated diseases of National Administration of Traditional Chinese Medicine: hepatic fibrosis

向作者/读者索取更多资源

This study investigated the safety and antibody responses of COVID-19 vaccination in patients with chronic hepatitis B (CHB) virus infection. The results showed that the vaccine was well tolerated and induced effective antibody responses in CHB patients.
Background and Aims The safety and antibody responses of coronavirus disease 2019 (COVID-19) vaccination in patients with chronic hepatitis B (CHB) virus infection is still unclear, and exploration in safety and antibody responses of COVID-19 vaccination in CHB patients is significant in clinical practice. Methods 362 adult CHB patients and 87 healthy controls at an interval of at least 21 days after a full-course vaccination (21-105 days) were enrolled. Adverse events (AEs) were collected by questionnaire. The antibody profiles at 1, 2 and 3 months were elucidated by determination of anti-spike IgG, anti-receptor-binding domain (RBD) IgG, and RBD-angiotensin-converting enzyme 2 blocking antibody. SARS-CoV-2 specific B cells were also analysed. Results All AEs were mild and self-limiting, and the incidence was similar between CHB patients and controls. Seropositivity rates of three antibodies were similar between CHB patients and healthy controls at 1, 2 and 3 months, but CHB patients had lower titers of three antibodies at 1 month. Compared to healthy controls, HBeAg-positive CHB patients had higher titers of three antibodies at 3 months (all P < .05) and a slower decline in antibody titers. Frequency of RBD-specific B cells was positively correlated with titers of anti-RBD IgG (OR = 1.067, P = .004), while liver cirrhosis, antiviral treatment, levels of HBV DNA, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and total bilirubin (TB) were not correlated with titers of anti-RBD IgG. Conclusions Inactivated COVID-19 vaccines were well tolerated, and induced effective antibody response against SARS-CoV-2 in CHB patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据